A Partnership to End
the Global Anxiety Epidemic
The formal commercialisation of a discovery made in 1996 that global systems are only now ready to deploy.
The Charles Linden Institute invites acquisition, equity, licensing and strategic partnership discussions with health tech partners, institutional investors and corporate acquirers who understand the scale of what is on offer.
Request the Full DeckThe Only Mental Health Market
Still Awaiting Its Insulin Moment
Every other chronic disease category has experienced a defining scientific breakthrough — a moment when management gave way to resolution. Anxiety has not. Until now.
Anxiety is the largest mental health burden on the planet
1 in 4 people globally. Over €1 trillion in annual economic loss. The most prevalent, most costly, and most untreated condition in modern medicine.
Every existing solution manages symptoms — none resolve the disorder
CBT, medication, EFT, EMDR and talking therapy operate downstream of the subcortical threat-response system. They manage output. The alarm never stops.
No technology has ever reset the threat-response mechanism — until now
The Linden Method directly addresses the biological process by which fear permanently deactivates. Identified, operationalised and proven across 30 years and 650,000+ recoveries.
This is not a product launch. It is a market correction.
When insulin was discovered, every prior management protocol became obsolete overnight. That structural moment is arriving for anxiety. The platform shift has already begun.
"Linden discovered how fear actually turns off — and became the first to inject that science into recovery practice. He created the first and only scientifically verifiable recovery therapy."
What Tiny Market Share Means at Scale
Based on the global anxiety conditions treatment market — valued at €21B today, rising to €28B+ by 2030 (CAGR 10%). Each figure below represents a single sector; institutional coaching deployment multiplies these numbers significantly.
| Market Share | Context | Now | 2030 |
|---|---|---|---|
| 0.1% | Conservative early-stage digital adoption — achievable within 12–18 months | Contact | Contact |
| 0.5% | Modest growth across digital, corporate and residential channels within 3 years | Contact | Contact |
| 1% | Established market presence — employer contracts, insurer partnerships, multi-region | Contact | Contact |
| 5% | Category leadership — realistic long-term position for the world's only curative provider | Contact | Contact |
Why This Is Not a Speculative Investment
Conservative capital allocates to structural certainty — not speculative potential. Every standard category of investment risk has already been resolved.
R&D Risk Eliminated
No research phase. No development required. Four platforms are live, operational and generating revenue today. The asset exists and performs.
Regulatory Risk Eliminated
Psycho-educational delivery requires no clinical registration, no medical device approval and no clinical oversight chain. Deploy at scale from day one.
Platform Risk Eliminated
An independent multi-platform ecosystem — digital, residential, professional and diagnostic — each operationally self-sustaining and revenue-positive.
Competitive Risk Eliminated
The 30-year dataset is the product. It cannot be replicated regardless of capital, timeline or intent. The moat is biological time and lived outcomes.
"Neurological recalibration is a biological mechanism — not a trend, not a framework, not a methodology. It cannot be disrupted. Evolution built it. Charles Linden found it."
Flexible Structures for the Right Partner
Full Acquisition
Purchase of the Linden Method IP, platforms and programmes — outright ownership of a globally unique asset.
Partial Acquisition
Equity stake in the organisation with agreed commercial rights and joint development of new market verticals.
Paid Partnership
Structured commercial agreement — licensing, revenue share or co-brand — with defined territory and vertical rights.
Strategic Alliance
Long-term joint venture for market expansion across corporate, healthcare, education and public sector channels.
Open the Allocation
Conversation
Submit your details below and our team will send you the full 2026 Global Health Tech Initiative deck — including detailed financial projections, full IP inventory, platform data, and partnership terms.
Open the allocation conversation
A direct discussion to determine the appropriate structure — acquisition, equity or formal partnership.
Full platform and IP review
Complete access to programme content, platform assets, audience data and commercial documentation.
Term sheet and commercial negotiation
Agree structure, valuation, territory rights and revenue arrangements — with full flexibility.
Execution and market launch
Agreement executed and partnership activated — with Charles Linden directly involved in market positioning and launch strategy.
